Pain Med
4151-A UNMET SYSTEMIC THERAPY NEED FOR CHILD-PUGH CLASS B PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA COMPARISON OF ATEZOLIZUMAB PLUS BEVACIZUMAB AND LENVATINIB Hideko Ohama 1,2,3 , Atsushi Hiraoka 1,2 , Toshifumi Tada 2 , Masashi Hirooka 2 , Kazuya Kariyama 2 , Ei Itobayashi 2 , Tsuji Kunihiko 2 , Toru Ishikawa 2 , Hidenori Toyoda 2 , Takeshi Hatanaka 2 , Satoru Kakizaki 2 , Atsushi Naganuma 2 , Tomomitsu Matono 2 , Fujimasa Tada 1,2 , Kazuhiro Nouso 2 , Yoichi Hiasa 2 and Takashi Kumada 2 , (1)Ehime Prefectural Central Hospital, (2)Relpec Study Group and HCC 48 Group, (3)Takarazuka City Hospital Background: Systemic treatment is generally recommended for unresectable hepatocellular carcinoma (uHCC) patients with Child-Pugh (CP)-A status
Required Equipment and Materials Plate reader (405 or 415 nm filter) 96-well microplate Incubator (37C) 20 l and 200 l pipettes, a multi channel pipette 5-Sulfosalicylic Acid (SSA) Solution Ethanol Assay Procedure Sulfasalazine Alters Intracellular Metabolites and Increases ROS in A549 Cells Induction of Ferroptosis by Erastin Erastin is a known inducer of ferroptosis
da CostaRMRodriguesDPereiraCASilvaJFAlvesJVLobatoNSet alNrf2 as a potential mediator of cardiovascular risk in metabolic diseases
